Risk Factors for Urologic Complications After Kidney Transplantation and Impact in Graft Survival.

IF 2 Q2 UROLOGY & NEPHROLOGY
Research and Reports in Urology Pub Date : 2022-09-28 eCollection Date: 2022-01-01 DOI:10.2147/RRU.S371851
Laura Nino-Torres, Andrea Garcia-Lopez, Nasly Patino-Jaramillo, Fernando Giron-Luque, Alejandro Nino-Murcia
{"title":"Risk Factors for Urologic Complications After Kidney Transplantation and Impact in Graft Survival.","authors":"Laura Nino-Torres,&nbsp;Andrea Garcia-Lopez,&nbsp;Nasly Patino-Jaramillo,&nbsp;Fernando Giron-Luque,&nbsp;Alejandro Nino-Murcia","doi":"10.2147/RRU.S371851","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Kidney transplantation (KT) is the best therapy for chronic kidney disease (CKD). Major urologic complications (MUCs) are the second etiology associated to morbidity and graft loss following KT, after rejection episodes. The objective of this study was to estimate the incidence, risk factors and impact on graft survival associated to urological complications in KT patients.</p><p><strong>Patients and methods: </strong>A retrospective cohort based on electronic patient files of kidney transplant recipients from Colombiana de Trasplantes was created for the period August 2008 to September 2019. Initiation of follow-up was defined as the date of transplantation up to 3 years post-transplantation. Incidence of ureteral stenosis, ureteral obstruction, and ureteral leak was measured. A logistic regression multivariate model was adjusted to determine the associated factors to MUCs (yes/no). Patient and graft survival time were analyzed using a Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 1584 KT patients were included in the cohort. MUCs were present in 195 (12.6%) KT patients. We found that dialysis duration (OR: 1.004; p = 0.02) remained significant for the incidence of MUCs in KT patients of deceased donors. Probability of graft and patient survival at 3 years of follow-up was 90.5% and 85.5%, respectively. No significant difference was found on graft and patient survival in KT patients with or without MUCs.</p><p><strong>Conclusion: </strong>MUCs are frequent complications for KT. We did not observe significant differences in graft or patient survival according to the presence of MUCs. The identification of MUCs and risk factors may guide transplant teams for future surgical and clinical decisions.</p>","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/1a/rru-14-327.PMC9527029.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRU.S371851","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Background and purpose: Kidney transplantation (KT) is the best therapy for chronic kidney disease (CKD). Major urologic complications (MUCs) are the second etiology associated to morbidity and graft loss following KT, after rejection episodes. The objective of this study was to estimate the incidence, risk factors and impact on graft survival associated to urological complications in KT patients.

Patients and methods: A retrospective cohort based on electronic patient files of kidney transplant recipients from Colombiana de Trasplantes was created for the period August 2008 to September 2019. Initiation of follow-up was defined as the date of transplantation up to 3 years post-transplantation. Incidence of ureteral stenosis, ureteral obstruction, and ureteral leak was measured. A logistic regression multivariate model was adjusted to determine the associated factors to MUCs (yes/no). Patient and graft survival time were analyzed using a Kaplan-Meier method.

Results: A total of 1584 KT patients were included in the cohort. MUCs were present in 195 (12.6%) KT patients. We found that dialysis duration (OR: 1.004; p = 0.02) remained significant for the incidence of MUCs in KT patients of deceased donors. Probability of graft and patient survival at 3 years of follow-up was 90.5% and 85.5%, respectively. No significant difference was found on graft and patient survival in KT patients with or without MUCs.

Conclusion: MUCs are frequent complications for KT. We did not observe significant differences in graft or patient survival according to the presence of MUCs. The identification of MUCs and risk factors may guide transplant teams for future surgical and clinical decisions.

Abstract Image

Abstract Image

肾移植术后泌尿系统并发症的危险因素及对移植物存活的影响。
背景与目的:肾移植是治疗慢性肾脏疾病的最佳方法。主要泌尿系统并发症(MUCs)是继排异反应后KT术后发病率和移植物损失的第二大病因。本研究的目的是评估KT患者泌尿系统并发症的发生率、危险因素及其对移植物存活的影响。患者和方法:基于2008年8月至2019年9月期间哥伦比亚移植医院肾移植受者的电子患者档案,建立了一个回顾性队列。开始随访定义为移植日期至移植后3年。测量输尿管狭窄、输尿管梗阻和输尿管漏的发生率。调整logistic回归多变量模型以确定与MUCs相关的因素(是/否)。采用Kaplan-Meier法分析患者和移植物存活时间。结果:该队列共纳入1584例KT患者。195例(12.6%)KT患者存在MUCs。我们发现透析持续时间(OR: 1.004;p = 0.02)在死亡供者的KT患者中MUCs的发生率仍然显著。3年随访时移植成功率和患者生存率分别为90.5%和85.5%。有无MUCs的KT患者在移植物和患者生存方面无显著差异。结论:MUCs是KT的常见并发症。我们没有观察到移植或患者生存因MUCs的存在而有显著差异。MUCs和危险因素的识别可以指导移植团队未来的手术和临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Research and Reports in Urology
Research and Reports in Urology UROLOGY & NEPHROLOGY-
CiteScore
3.40
自引率
0.00%
发文量
60
审稿时长
16 weeks
期刊介绍: Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信